Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Published:2021-11 Issue:11 Volume:41 Page:5811-5816
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

KATO TAIGO,NAGAHARA AKIRA,KAWAMURA NORIHIKO,NAKATA WATARU,SODA TETSUJI,MATSUZAKI KYOSUKE,HATANO KOJI,KAWASHIMA ATSUNARI,UJIKE TAKESHI,IMAMURA RYOICHI,NISHIMURA KENSAKU,TAKADA SHINGO,TSUJIHATA MASAO,YAMAGUCHI SEIJI,TAKAO TETSUYA,NAKAI YASUTOMO,NAKAYAMA MASASHI,NONOMURA NORIO,UEMURA MOTOHIDE

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review;Cancers;2024-07-20

2. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review;Cancer Treatment Reviews;2024-01

3. Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy;Anticancer Research;2022-08-23

4. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study);Japanese Journal of Clinical Oncology;2022-08-03

5. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma;Anticancer Research;2022-01-29